Jennifer K. Litton, MD, and Ann H. Partridge, MD, on Breast Cancer in Young Women
2016 San Antonio Breast Cancer Symposium
Jennifer K. Litton, MD, of MD Anderson Cancer Center, and Ann H. Partridge, MD, of the Dana-Farber Cancer Institute, discuss a range of issues for young women with breast cancer, including epidemiologic and biologic differences in younger patients, fertility issues, and pregnancy-associated breast cancer (Poster Discussion 6).
Lisa A. Carey, MD, and Maki Tanioka, MD, both of the University of North Carolina, discuss study findings on weekly paclitaxel and trastuzumab with or without lapatinib for HER2-positive breast cancer (Abstract S3-05).
Samuel Smith, PhD, of Queen Mary University of London, discusses study findings on menopausal symptoms as predictors of long‐term adherence in an International breast cancer intervention study (Abstract S5-03).
Jame Abraham, MD, of the Cleveland Clinic, discusses findings of the Scalp Cooling Alopecia Prevention trial for patients with early-stage breast cancer (Abstract S5-02).
Nikhil Wagle, MD, Dana-Farber Cancer Institute, discusses the genomic sequencing of ER-positive metastatic breast cancer that has become resistant to therapies and the implications for the choice of next therapy, clinical trial eligibility, and novel drug targets (Abstract S1-01).
Jame Abraham, MD, of the Cleveland Clinic, gives his perspective on study results of extended adjuvant endocrine therapy in postmenopausal women with estrogen receptor–positive breast cancer who have completed previous adjuvant endocrine treatment (Abstract S1-05).